For the year ending 2025-12-31, IGC had $495K increase in cash & cash equivalents over the period. -$4,769K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -4,146 |
| Depreciation and amortization | 324 |
| Provision for bad debt | 0 |
| Impairment of assets | 0 |
| Common stock-based compensation and expenses, net | 2,108 |
| Other non-cash items | -3,234 |
| Accounts receivable, net | -22 |
| Inventory | -36 |
| Deposits and advances | -195 |
| Claims and advances | -11 |
| Accounts payable | 132 |
| Accrued and other liabilities | -248 |
| Operating lease asset | -87 |
| Operating lease liability | -7 |
| Net cash used in operating activities | -4,720 |
| Purchase of property, plant, and equipment | 49 |
| Sale of property, plant, and equipment | 681 |
| Investment in short-term investments | 50 |
| Acquisition and development of intangible assets | 604 |
| Net cash from (used) in investing activities | -22 |
| Proceeds from common stock subscribed | 5,228 |
| Repayment of long-term loan | 3 |
| Net cash provided by financing activities | 5,225 |
| Effects of exchange rate changes on cash and cash equivalents | 12 |
| Net increase (decrease) in cash and cash equivalents | 495 |
| Cash and cash equivalents at the beginning of the period | 405 |
| Cash and cash equivalents at the end of the period | 900 |
IGC Pharma, Inc. (IGC)
IGC Pharma, Inc. (IGC)